KRAS analysis vaults Merck's flagship Keytruda back into the spotlight
The jewel in Merck’s crown — Keytruda — just got more precious.
On Thursday, the US drugmaker broke out an exploratory analysis showing the checkpoint inhibitor …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
